What Money Can't Buy: The Unique Offerings of Patient Group Investors

How can patient advocacy groups attract an early-stage company to develop technology for their community? When a patient organization acts as an investor, they may have more to offer than just money.

Amid a competitive, yet uncertain marketplace, how do companies decide which disease areas to target with their technologies? Making this decision with the right partners is critical, and early-stage companies should consider the tools, resources, and expertise that patient organizations can provide. Opportunities for connection and collaboration can be the difference between failure and success.
This session will provide examples of what kinds of support beyond the dollar — such as clinical samples, patient registry data, and regulatory assistance — can help supplement an investment to build fruitful relationships that lead to progress for the most vulnerable patients. This session will discuss the Cystic Fibrosis and Michael J. Fox Foundations’ collaborations with 4D Molecular Therapeutics and AbbVie, respectively.